RESOURCES

How much of your compound’s activity are your assays really detecting? Understanding how receptor density impacts pharmacological responses is critical for accurately characterizing compound activity & identifying candidates with the highest likelihood of therapeutic success. Review the latest GPCR white paper, “Functional ‘Volume Control’ in Cell Systems,” by GPCR expert Terry Kenakin, Ph.D., Professor of Pharmacology at the University of North Carolina School of Medicine, in collaboration with Eurofins DiscoverX^®. The white paper explores how tuning receptor density & system sensitivity can uncover hidden efficacies, improve characterization of agonists & antagonists, & provide more predictive pharmacology.

Early safety insights can make or break a program. Discover how current industry thinking and practical strategies to help you apply secondary pharmacology more effectively, so you can make risk-informed decisions earlier.

For Translational Insights in Metabolic Discovery and Development

Accelerate innovation with complete kinase solutions

Neurotoxicity is a major cause of drug attrition with central nervous system (CNS) affected the most.

Class B GPCR Target Significance

WEE1 is a key regulator of the G2/M cell cycle checkpoint, inhibiting CDK1 to allow DNA repair before mitosis.

Our team partnered with an early-stage biotech on an A_2A receptor antagonist program initially targeting Parkinson’s disease.

Dose-response Relationships Across Clinically Relevant Human Targets

Assessing Fcγ receptor (FcγR) binding is an essential part of therapeutic antibody characterization, as these interactions influence a molecule’s effector function, safety profile, and mechanism of action.

Drug-induced Liver Injury (DILI) remains a major obstacle in drug development. Despite the use of various models, DILI continues to lead to drug attrition, post-market withdrawals, and safety warnings.

Clinical attrition of drug candidates is frequently driven by unforeseen safety liabilities, which are often associated with off-target pharmacological interactions.